Paper41211166
Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.
Parola S and 1 other. Explor Target Antitumor Ther, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. Papers, record 41211166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41211166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References133
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39273684 | Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39273684 | PubMed |
| 2 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 3 | 26295610 | T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. | Blood Cancer J | 2015 | https://conductscience.org/library/papers/26295610 | PubMed |
| 4 | 34011961 | A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. | Sci Rep | 2021 | https://conductscience.org/library/papers/34011961 | PubMed |
| 5 | 39735605 | The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy. | Front Oncol | 2024 | https://conductscience.org/library/papers/39735605 | PubMed |
| 6 | 31544849 | Design and Production of Bispecific Antibodies. | Antibodies (Basel) | 2019 | https://conductscience.org/library/papers/31544849 | PubMed |
| 7 | 36936577 | Endometrial cancer: molecular classification and future treatments. | BMJ Med | 2022 | https://conductscience.org/library/papers/36936577 | PubMed |
| 8 | 38252906 | Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. | Blood | 2024 | https://conductscience.org/library/papers/38252906 | PubMed |
| 9 | 33088681 | Recent advances of antibody drug conjugates for clinical applications. | Acta Pharm Sin B | 2020 | https://conductscience.org/library/papers/33088681 | PubMed |
| 10 | 34922633 | Recent advances and challenges of bispecific antibodies in solid tumors. | Exp Hematol Oncol | 2021 | https://conductscience.org/library/papers/34922633 | PubMed |
| 11 | 25437562 | Structure and cancer immunotherapy of the B7 family member B7x. | Cell Rep | 2014 | https://conductscience.org/library/papers/25437562 | PubMed |
| 12 | 23851282 | Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. | Methods | 2014 | https://conductscience.org/library/papers/23851282 | PubMed |
| 13 | 37304291 | Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. | Front Immunol | 2023 | https://conductscience.org/library/papers/37304291 | PubMed |
| 14 | 38339430 | Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know? | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339430 | PubMed |
| 15 | 28249141 | Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28249141 | PubMed |
| 16 | 37857711 | The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37857711 | PubMed |
| 17 | 40427532 | Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy. | Biomolecules | 2025 | https://conductscience.org/library/papers/40427532 | PubMed |
| 18 | 19840887 | Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/19840887 | PubMed |
| 19 | 28916367 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2017 | https://conductscience.org/library/papers/28916367 | PubMed |
| 20 | 28182247 | Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. | Clin Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28182247 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42649936 | Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649936 | PubMed |
| 42494820 | Targeting glucocorticoid receptor signaling in platinum-resistant ovarian cancer: translational rationale and clinical advances following the ROSELLA trial. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42494820 | PubMed |
| 41827159 | Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827159 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41211166
GET https://conductscience.org/api/papers/v1/41211166/references?page=2